Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier AH, Hermanides RS, Ottervanger JP, Rasoul S, Slingerland RJ, Tolsma R, van Workum S, Kedhi E, van 't Hof AWJ. Tavenier AH, et al. Neth Heart J. 2019 Apr;27(4):185-190. doi: 10.1007/s12471-019-1241-6. Neth Heart J. 2019. PMID: 30767166 Free PMC article.
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW. Hermanides RS, et al. Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20. Heart. 2011. PMID: 20962338 Clinical Trial.
Use, timing and outcome of coronary angiography in patients with high-risk non-ST-segment elevation acute coronary syndrome in daily clinical practice: insights from a 'real world' prospective registry.
Badings EA, Hermanides RS, Van Der Sluis A, Dambrink JHE, Gosselink ATM, Kedhi E, Ottervanger JP, Roolvink V, Remkes WS, Van't Riet E, Suryapranata H, Van't Hof AWJ. Badings EA, et al. Neth Heart J. 2019 Feb;27(2):73-80. doi: 10.1007/s12471-018-1212-3. Neth Heart J. 2019. PMID: 30547413 Free PMC article.
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry.
Selvarajah A, Tavenier AH, Bor WL, Houben V, Rasoul S, Kaplan E, Teeuwen K, Hofma SH, Lipsic E, Amoroso G, van Leeuwen MAH, Berg JMT, van 't Hof AWJ, Hermanides RS. Selvarajah A, et al. BMC Cardiovasc Disord. 2021 Jun 12;21(1):292. doi: 10.1186/s12872-021-02093-4. BMC Cardiovasc Disord. 2021. PMID: 34118880 Free PMC article.
333 results